© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Cancer Network spoke with Dr. Ahmed Kaseb about a phase II pilot trial of perioperative immunotherapy for resectable HCC and how the results could change future perioperative treatment of the disease.
Cancer Network spoke with Dr. Ahmed Kaseb about a phase II pilot trial of perioperative immunotherapy for resectable HCC and how the results could change future perioperative treatment of the disease.
Related Content: